His Lly Us5324571083 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eli Lilly said on Friday its drug Emgality did not meet the primary goal of superiority to Pfizer Inc s Nurtec ODT in prevention of episodic migraine in a post-approval study. This was. | June 16, 2023

Lilly emgalityShinjini ganguliEli lillyLeroy leoPfizer inc nurtecPfizer incEli lilly and company stock exchangePress releaseHis lly us5324571083